Prostate Cancer Update
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.
Show episodes
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Prostate Cancer
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with prostate cancer.
Oncology Today with Dr Neil Love: Management of Metastatic Urothelial Bladder Cancer
Dr Michiel van der Heijden from the Netherlands Cancer Institute in Amsterdam discusses the management of metastatic urothelial bladder cancer.
Oncology Today with Dr Neil Love: An interview with Matthew R Smith, MD, PhD — Management of Prostate Cancer
Dr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer.
Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma: A Post-ASCO Annual Review
Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma.
Oncology Today with Dr Neil Love: Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer
Dr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer.
Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder Cancer
Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting.